Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: J Thromb Haemost. 2019 Oct 16;18(1):180–190. doi: 10.1111/jth.14642

Fig. 3.

Fig. 3.

Effect of FPX on markers of leukocyte and complement activation. (A) Myeloperoxidase (MPO), (B) Citrullinated histone H3, (C) complement activation product C3b, (D) complement terminal complex C5b-9, and (E) high mobility group box 1 (HMGB1) in septic baboons without (LD100) or with FPX treatment (LD100+ FPX). Data are presented as mean ± SEM. For all graphs, asterisks indicate a statistically significant difference between LD100 and LD100+FPX, as calculated with the linear mixed effects model (*P < 0.05, **P <0.01, ***P < 0.001).